Coloplast : Q3 2021-22 results due on 17 August – in line with previous quarters
>Homogenous development among the segments - Q3 2021-22 revenues of DKK 5,720m (+18.3% y-o-y, slightly below the consensus) should be supported by solid organic growth of 6.6% (consensus 6.4%), in line with the quarterly performance in the first half. It is our view that the lockdowns in China have had some impact on quarterly growth. We calculate an external growth contribution related to Atos Medical of 870bp with corresponding revenues of DKK 420m for the new Voice...Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.